Journal of Virology, May 2001, p. 4448-4452, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4448-4452.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Division of Comparative Pathology, New England Regional Primate Research Center, Harvard Medical School, Southborough, Massachusetts 01772
Received 20 October 2000/Accepted 24 January 2001
| |
ABSTRACT |
|---|
|
|
|---|
The influence of host cytokine response on viral load, disease
progression, and neurologic lesions was investigated in the simian
immunodeficiency virus (SIV)-infected macaque model of AIDS. Cytokine
gene expression (interleukin-1
[IL-1
], IL-2, IL-6, IL-10, gamma
interferon [IFN-
], and tumor necrosis factor alpha [TNF-
])
and viral loads were evaluated by semiquantitative reverse
transcription-PCR in lymph nodes of 5 control animals and 28 animals
infected with SIVmac251 at the terminal stages of AIDS. Infected
animals showed higher expression of IFN-
, IL-6, and IL-10 mRNAs
compared with controls. Levels of all cytokines were comparable between
animals with rapid (survival, <200 days) or slow/normal (survival,
>200 days) disease progression. However, among rapid progressors, the
eight animals with SIV encephalitis had a unique cytokine profile
(increased IL-2, IL-6, and IFN-
) that was associated with higher
viral loads. These observations provide evidence that host cytokine
responses may influence SIV neuropathogenesis independent of disease progression.
| |
TEXT |
|---|
|
|
|---|
Dysregulation of the cytokine
network is postulated to play a role in the pathogenesis of human
immunodeficiency virus type 1 (HIV-1) infection. It has been proposed
that the progression of HIV infection is accompanied by a shift in the
cytokine expression profile from a predominant T helper type 1 (Th1)
cytokine profile (production of interleukin-2 [IL-2] and gamma
interferon [IFN-
]) to a T helper type 2 (Th2) cytokine profile
(production of IL-4 and IL-10). While evidence from several studies
with adults (5, 6) and children (27) supports
this notion, not all data fit the proposed Th1/Th2 switch in HIV
disease progression (8, 25, 33).
Cytokines can influence disease pathogenesis through a variety of direct and indirect mechanisms. Cytokines that induce cellular activation and/or proliferation have been shown to promote infection and replication of HIV in vitro (1, 2, 4). Inflammatory cytokines may influence viral pathogenesis by modulating expression of chemokines in monocytes (23) and chemokine receptors in CD4+ T cells (2, 35), which are important in leukocyte recruitment and function as coreceptors for HIV.
A number of studies have addressed early cytokine responses in peripheral blood and lymph nodes during primary simian immunodeficiency virus (SIV) infection, focusing on events during the first several weeks to months following infection (3, 4, 13, 14). However, few reports have investigated the role of host cytokine responses in disease pathogenesis and the subsequent development of pathology. To explore the association of cytokine expression with disease progression, viral burden, and neuropathologic status, we examined cytokine profiles in peripheral lymph nodes from subgroups of rhesus macaques infected with SIVmac251.
Thirty-three juvenile and adult rhesus macaques (Macaca mulatta) were evaluated retrospectively. Twenty-eight animals were inoculated intravenously with uncloned SIVmac251 and sacrificed at the terminal stages of AIDS. Five age-matched uninfected control animals were also evaluated. Virus stocks and doses have been described previously (15, 26, 32). Survival time among infected animals ranged from 111 to 854 days postinoculation (dpi) with an average survival of 333 days. Sixteen animals showed a rapid disease course with progression to AIDS by 200 dpi (mean survival, 157 days), with the remaining 12 animals having slow/normal disease progression with survival longer than 200 days (mean survival, 567 days).
The diagnosis of SIV encephalitis (SIVE) in infected animals was based
on the presence of perivascular accumulations of macrophages and
multinucleated giant cells and by virus infection within the central
nervous system (CNS) demonstrated by in situ hybridization as
previously described (14-16, 31). Riboprobes for virus
localization were kindly provided by Vanessa Hirsch and Charles Brown,
National Institute of Allergy and Infectious Diseases, Rockville, Md., and have been described elsewhere (11). Using these
methods we found that 9 of 28 (32.1%) infected animals showed
histologic evidence of SIVE (Fig. 1). The
majority of these animals (8 of 9) were rapid progressors (mean
survival, 155 days), in accordance with previously published data
(30).
|
To evaluate viral load and levels of IL-1
, IL-2, IL-6, IL-10,
IFN-
, and tumor necrosis factor alpha (TNF-
) mRNA in lymph nodes
of rhesus macaques infected with SIVmac251, we used semiquantitative reverse transcription-PCR. Total RNA was extracted from 30 mg of
snap-frozen axillary lymph node using the SV Total RNA Isolation Kit
(Promega, Madison, Wis.), and reverse transcription-PCR was performed
as described previously (17). The optimal number of PCR
cycles was determined initially by using a variable number of cycles to
identify a linear range of amplification for each transcript.
-Actin
cDNAs were amplified using primers modified from those previously
described (23), and cytokines (IL-1
, IL-2, IL-6, IL-10,
IFN-
, and TNF-
) were detected using published sequences
(28). Levels of SIV env transcripts were also
evaluated using the following primers: 5'-GGAATCAGCTGCTTATCG-3'
and 5'-AGCTTTCTGTAACATTAAGG-3'. Twenty microliters of
PCR products was electrophoresed through a 2% agarose gel, stained
with ethidium bromide, and then visualized under ultraviolet light.
Images were captured and band densitometry was assayed using the Gel
Doc 2000 PCI system and Quantity One software (Bio-Rad, Hercules,
Calif.). All densities were normalized against respective
-actin
signals obtained from the same sample, and the data were expressed as
the ratios of signal obtained from the mRNA of interest over the signal
obtained from
-actin mRNA. Control and SIV-infected groups were
compared using Student's t tests, and a P value
of <0.05 was considered statistically significant.
Overall, levels of IFN-
, IL-6, and IL-10 mRNA expression were
significantly increased (P < 0.003, P < 0.04, and P = 0.001, respectively) in lymph nodes
from SIV-infected animals (n = 28) compared to
uninfected controls (n = 5) (Fig.
2). Levels of IL-2 mRNA were increased
slightly in infected animals but this was not significant (P = 0.18). Expression of TNF-
and IL-1
mRNA was unchanged
following infection. To determine if rapid disease progression in
SIV-infected animals was associated with a specific cytokine response,
cytokine mRNAs were compared for animals with rapid (n = 16) and slow/normal (n = 12) progression. We were
surprised to find that there were no significant differences between
the two groups of animals in any of the cytokines evaluated (Fig. 3). Levels of IL-2 mRNA tended to be
higher for rapid progressors, but this was not significant
(P = 0.06). These data suggest that rapid disease
progression, in general, is not associated with a unique host cytokine
response in the SIV-infected macaque, but rather there appears to be a
common cytokine profile present in animals at the terminal stages of
disease.
|
|
Previous studies in our laboratory have shown that approximately 25%
of all macaques infected with pathogenic SIV develop SIVE. However,
among rapid progressors the incidence of SIVE was increased with
approximately 50% of these animals demonstrating characteristic CNS
lesions (30). We were therefore interested in examining
cytokine profiles in this subpopulation of rapid progressors. Although
cytokine profiles were indistinguishable among rapid and slow/normal
progressors, when rapid progressors were divided into those with SIVE
(n = 8) and those without (n = 8), it
became clear that encephalitic animals had a unique cytokine profile.
Rapid progressors with SIVE showed a predominant Th1 cytokine response
(Fig. 4) with significantly higher levels
of IFN-
and IL-2 (P = 0.045 and P = 0.004, respectively). Increased expression of IL-6 mRNA
(P = 0.008) was also observed in rapid progressors with
encephalitis. The overall cytokine profile for rapid progressors
without encephalitis did not differ significantly from that observed
for animals with slow/normal progression.
|
Levels of IL-2 and IL-6 in rapid progressors without encephalitis and
in slow/normal progressors were not significantly different from those
of control animals. However, IL-6 was increased in all infected animals
compared to controls (Fig. 2). Thus, the elevation of IL-6 we observed
in infected animals overall was due almost entirely to the contribution
of rapid progressors with SIVE. Although IL-10 was increased from that
of controls for all groups of SIV-infected animals, levels were not
significantly different among the three groups of infected animals
(Fig. 4). Expression of IL-1
and TNF-
was not significantly
different among the three groups of SIV-infected animals and controls.
In general, two distinct patterns of cytokine expression were evident
in lymph nodes of macaques infected with SIV. The predominant profile,
which was present in slow/normal progressors and rapid progressors
without SIVE (20 of 28 infected animals; 71%), was typified by
overexpression of IFN-
and IL-10 mRNAs. In these animals, levels of
IL-2 and IL-6 were comparable to those of controls. The less prevalent
profile, which was seen in animals with rapid disease progression and
SIVE (8 of 28 infected animals; 29%), was also characterized by
overexpression of IFN-
and IL-10. However, lymph nodes from these
animals also contained higher levels of IL-2 and IL-6 mRNA compared to
control animals and other groups of SIV-infected animals (Fig. 4).
Levels of IFN-
and IL-10 transcripts were increased from control
values in all groups of infected animals, although there was some
degree of variation in the magnitude of response among the groups.
Similar increases in IL-10 and IFN-
have also been reported in
intestinal lymphocytes from chronically SIV-infected animals
(24). From this we may conclude that induction of IFN-
and IL-10 mRNAs is a generalized response to SIV infection and that
overexpression of these two cytokines alone is not directly related to
disease progression or neuropathologic outcome of infection. In
contrast, IL-2 and IL-6 mRNAs were increased only in the subpopulation of infected animals with rapid disease progression and histologic lesions of SIVE. These findings suggest that this particular cytokine profile is not a universal response to SIV infection but is limited to
a subpopulation of infected macaques that develop SIVE.
To understand the relationship of host cytokine response with the
control of virus replication in vivo, viral loads were evaluated in
lymph nodes and then correlated with cytokine profiles. In comparing
viral burdens in lymph nodes of macaques with rapid and slow/normal
disease progression, we found that there was no significant difference
between these two groups of infected animals (Table
1), although there was a trend towards
higher viral loads in rapid progressors (P = 0.07).
Similarly, rapid progressors without SIVE and slow/normal progressors
showed no difference in viral loads. This was not entirely surprising
based on the finding that overall cytokine profiles were
indistinguishable between these groups of infected animals. However,
when we analyzed viral loads in rapid progressors with SIVE, we found
that the distinct cytokine profile in lymph nodes of macaques in this
group was associated with significantly higher viral burdens
(P = 0.016) compared to rapid progressors without SIVE.
Higher viral loads in cerebrospinal fluid and brain tissues have been
correlated with the presence and severity of CNS lesions in pigtailed
macaques infected with SIV (34), substantiating the
association of higher levels of viral RNA with the presence of SIVE.
|
The concurrent increases in viral loads with IL-2 and IL-6 mRNAs in rapid progressors with SIVE suggest a direct relationship between cytokines and viral replication in lymph nodes. The association of altered cytokine expression with higher viral burden in lymph nodes may reflect the inductive effects of IL-2 and IL-6 on virus replication, as has been reported with HIV replication in vitro (1, 4, 20, 29). Alternatively, IL-2 may increase CCR5 expression in CD4+ T cells as has been recently reported with HIV infection in vivo (35), potentially increasing the number of mononuclear cells susceptible to infection with HIV and SIV.
The presence of perivascular infiltrates of macrophages in the CNS is a key feature of encephalitis with SIV and HIV-1 infections, and an increased number of brain macrophages has been correlated with dementia in people with AIDS (10). HIV-infected patients with dementia also show expansion of a unique subset of peripheral blood monocytes with an activated phenotype (21), and it is possible that these activated monocytes migrate into the brain parenchyma resulting in increased numbers of brain macrophages (19). It is likely that alterations in cytokines in the periphery influence CNS disease pathogenesis via activation of monocytes/macrophages and/or brain microvascular endothelial cells, although the exact mechanisms remain unclear. IL-2 has been shown to have monocyte/macrophage-activating properties (7) and leads to activation of brain microvascular endothelium (9) resulting in elevations in cell adhesion molecules (18). Thus, it is possible that IL-2 plays a role in the neuropathogenesis of SIV infection via cellular activation mechanisms.
This study clearly demonstrates that the cytokine profile in SIV-infected macaques with rapid disease progression and SIVE reflects a distinct and unique host response to virus infection. Here we extend previous observations correlating rapid disease progression with the presence of SIVE to include specific host determinants in rapidly progressing animals that influence neuropathogenesis.
| |
ACKNOWLEDGMENTS |
|---|
We gratefully acknowledge the pathology staff at the NERPRC for tissue collection and histopathology. We also thank Daniel Shvetz, Brendon Thompson, Kristen Toohey, and Douglas Pauley for assistance.
This work was supported in part by Public Health Service grants RR00168, NS30769, NS37654, and NS35732. A. Lackner is the recipient of an Elizabeth Glaser Scientist Award.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: New England Regional Primate Research Center, Harvard Medical School, One Pine Hill Dr., P.O. Box 9102, Southborough, MA 01772-9102. Phone: (508) 624-8018. Fax: (508) 624-8181. E-mail: andrew_lackner{at}hms.harvard.edu.
Present address: Beth Israel Deaconess Medical Center, Boston, MA 02215.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bayard-McNeeley, M., H. Doo, S. He, A. Hafner, W. D. Johnson, Jr., and J. L. Ho. 1996. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. Clin. Diagn. Lab. Immunol. 3:547-553[Abstract]. |
| 2. | Brice, G. T., A. E. Mayne, F. Villinger, and A. A. Ansari. 2000. A novel role for tumor necrosis factor-alpha in regulating susceptibility of activated CD4+ T cells from human and nonhuman primates for distinct coreceptor using lentiviruses. J. Acquir. Immune Defic. Syndr. 24:10-22. |
| 3. | Cheret, A., R. Le Grand, P. Caufour, N. Dereuddre-Bosquet, F. Matheux, O. Neildez, F. Theodoro, N. Maestrali, O. Benveniste, B. Vaslin, and D. Dormont. 1996. Cytokine mRNA expression in mononuclear cells from different tissues during acute SIVmac251 infection of macaques. AIDS Res. Hum. Retrovir. 12:1263-1272[Medline]. |
| 4. |
Chun, T. W.,
D. Engel,
S. B. Mizell,
L. A. Ehler, and A. S. Fauci.
1998.
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.
J. Exp. Med.
188:83-91 |
| 5. | Clerici, M., C. Balotta, L. Meroni, E. Ferrario, C. Riva, D. Trabattoni, A. Ridolfo, M. Villa, G. M. Shearer, M. Moroni, and M. Galli. 1996. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res. Hum. Retrovir. 12:1053-1061[Medline]. |
| 6. |
Clerici, M.,
M. L. Fusi,
S. Ruzzante,
S. Piconi,
M. Biasin,
D. Arienti,
D. Trabattoni, and M. L. Villa.
1997.
Type 1 and type 2 cytokines in HIV infection a possible role in apoptosis and disease progression.
Ann. Med.
29:185-188[Medline].
|
| 7. | Espinoza-Delgado, I., M. C. Bosco, T. Musso, G. L. Gusella, D. L. Longo, and L. Varesio. 1995. Interleukin-2 and human monocyte activation. J. Leukoc. Biol. 57:13-19[Abstract]. |
| 8. | Fan, J., H. Z. Bass, and J. L. Fahey. 1993. Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. J. Immunol. 151:5031-5040[Abstract]. |
| 9. | Gallo, P., S. Pagni, M. G. Piccinno, B. Giometto, V. Argentiero, M. Chiusole, F. Bozza, and B. Tavolato. 1992. On the role of interleukin-2 (IL-2) in multiple sclerosis (MS). IL-2-mediated endothelial cell activation. Ital. J. Neurol. Sci. 13:65-68[Medline]. |
| 10. | Glass, J. D., H. Fedor, S. L. Wesselingh, and J. C. McArthur. 1995. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 38:755-762[CrossRef][Medline]. |
| 11. | Hirsch, V., D. Adger-Johnson, B. Campbell, S. Goldstein, C. Brown, W. R. Elkins, and D. C. Montefiori. 1997. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J. Virol. 71:1608-1620[Abstract]. |
| 12. | Khatissian, E., L. Chakrabarti, and B. Hurtrel. 1996. Cytokine patterns and viral load in lymph nodes during the early stages of SIV infection. Res. Virol. 147:181-189[CrossRef][Medline]. |
| 13. | Khatissian, E., V. Monceaux, M. C. Cumont, L. Montagnier, B. Hurtrel, and L. Chakrabarti. 1996. Interferon-gamma expression in macaque lymph nodes during primary infection with simian immunodeficiency virus. Cytokine 8:844-852[CrossRef][Medline]. |
| 14. | Lackner, A. A., M. O. Smith, R. J. Munn, D. J. Martfeld, M. B. Gardner, P. A. Marx, and S. Dandekar. 1991. Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am. J. Pathol. 139:609-621[Abstract]. |
| 15. | Lane, J. H., V. G. Sasseville, M. O. Smith, P. Vogel, D. R. Pauley, M. P. Heyes, and A. A. Lackner. 1996. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J. Neurovirol. 2:423-432[Medline]. |
| 16. | Lane, J. H., A. F. Tarantal, D. Pauley, M. Marthas, C. J. Miller, and A. A. Lackner. 1996. Localization of simian immunodeficiency virus nucleic acid and antigen in brains of fetal macaques inoculated in utero. Am. J. Pathol. 149:1097-1104[Abstract]. |
| 17. | Levy, J. K., J. W. Ritchey, J. B. Rottman, M. G. Davidson, Y. H. Liang, H. L. Jordan, W. A. Tompkins, and M. B. Tompkins. 1998. Elevated interleukin-10-to-interleukin-12 ratio in feline immunodeficiency virus-infected cats predicts loss of type 1 immunity to Toxoplasma gondii J. Infect. Dis. 178:503-511. |
| 18. | Locker, G. J., S. Kapiotis, M. Veitl, R. M. Mader, B. Stoiser, J. Kofler, A. E. Sieder, H. Rainer, G. G. Steger, C. Mannhalter, and O. F. Wagner. 1999. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br. J. Haematol. 105:912-919[CrossRef][Medline]. |
| 19. | Persidsky, Y., M. Buttini, J. Limoges, P. Bock, and H. E. Gendelman. 1997. An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. J. Neurovirol. 3:401-416[Medline]. |
| 20. |
Poli, G.,
P. Bressler,
A. Kinter,
E. Duh,
W. C. Timmer,
A. Rabson,
J. S. Justement,
S. Stanley, and A. S. Fauci.
1990.
Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms.
J. Exp. Med.
172:151-158 |
| 21. | Pulliam, L., R. Gascon, M. Stubblebine, D. McGuire, and M. S. McGrath. 1997. Unique monocyte subset in patients with AIDS dementia. Lancet 349:692-695[CrossRef][Medline]. |
| 22. | Raff, T., M. van der Giet, D. Endemann, T. Wiederholt, and M. Paul. 1997. Design and testing of beta-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechniques 23:456-460[Medline]. |
| 23. |
Schmidtmayerova, H.,
H. S. Nottet,
G. Nuovo,
T. Raabe,
C. R. Flanagan,
L. Dubrovsky,
H. E. Gendelman,
A. Cerami,
M. Bukrinsky, and B. Sherry.
1996.
Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes.
Proc. Natl. Acad. Sci. USA
93:700-704 |
| 24. | Smit-McBride, Z., J. J. Mattapallil, F. Villinger, A. A. Ansari, and S. Dandekar. 1998. Intracellular cytokine expression in the CD4+ and CD8+ T cells from intestinal mucosa of simian immunodeficiency virus infected macaques. J. Med. Primatol. 27:129-140[Medline]. |
| 25. | Than, S., R. Hu, N. Oyaizu, J. Romano, X. Wang, S. Sheikh, and S. Pahwa. 1997. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J. Infect. Dis. 175:47-56[Medline]. |
| 26. |
Veazey, R. S.,
M. DeMaria,
L. V. Chalifoux,
D. E. Shvetz,
D. R. Pauley,
H. L. Knight,
M. Rosenzweig,
R. P. Johnson,
R. C. Desrosiers, and A. A. Lackner.
1998.
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.
Science
280:427-431 |
| 27. | Vigano, A., N. Principi, M. L. Villa, C. Riva, L. Crupi, D. Trabattoni, G. M. Shearer, and M. Clerici. 1995. Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J. Pediatr. 126:368-374[CrossRef][Medline]. |
| 28. | Villinger, F., S. S. Brar, A. Mayne, N. Chikkala, and A. A. Ansari. 1995. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J. Immunol. 155:3946-3954[Abstract]. |
| 29. | Weissman, D., J. Daucher, T. Barker, J. Adelsberger, M. Baseler, and A. S. Fauci. 1996. Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions. AIDS Res. Hum. Retrovir. 12:759-767[Medline]. |
| 30. | Westmoreland, S. V., E. Halpern, and A. A. Lackner. 1998. Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J. Neurovirol. 4:260-268[Medline]. |
| 31. |
Westmoreland, S. V.,
K. C. Williams,
M. A. Simon,
M. E. Bahn,
A. E. Rullkoetter,
M. W. Elliott,
C. D. deBakker,
H. L. Knight, and A. A. Lackner.
1999.
Neuropathogenesis of simian immunodeficiency virus in neonatal rhesus macaques.
Am. J. Pathol.
155:1217-1228 |
| 32. |
Wykrzykowska, J. J.,
M. Rosenzweig,
R. S. Veazey,
M. A. Simon,
K. Halvorsen,
R. C. Desrosiers,
R. P. Johnson, and A. A. Lackner.
1998.
Early regeneration of thymic progenitors in rhesus macaques infected with simian immunodeficiency virus.
J. Exp. Med.
187:1767-1778 |
| 33. | Zanussi, S., C. Simonelli, M. D'Andrea, C. Caffau, M. Clerici, U. Tirelli, and P. DePaoli. 1996. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin. Exp. Immunol. 105:220-224[CrossRef][Medline]. |
| 34. |
Zink, M. C.,
K. Suryanarayana,
J. L. Mankowski,
A. Shen,
M. Piatak, Jr.,
J. P. Spelman,
D. L. Carter,
R. J. Adams,
J. D. Lifson, and J. E. Clements.
1999.
High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis.
J. Virol.
73:10480-10488 |
| 35. | Zou, W., A. Foussat, S. Houhou, I. Durand-Gasselin, A. Dulioust, L. Bouchet, P. Galanaud, Y. Levy, and D. Emilie for the ANRS 048 IL-2 Study Group. 1999. Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. AIDS 13:455-463[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|